Funder: National Institutes of Health (NIH)

Due Dates: October 20, 2025 | February 20, 2026 | June 22, 2026 | October 20, 2026 | February 22, 2027 | June 21, 2027 | October 20, 2027 | February 22, 2028 | June 20, 2028

Funding Amounts: Up to $3,000,000 direct costs/year; maximum project period is 5 years (UG3: up to 2 years, UH3: up to 3 years).

Summary: Supports preclinical and clinical research to discover and develop interventions (medications, devices, digital therapeutics, behavioral treatments) to prevent or treat substance use disorders and overdose.

Key Information: UG3/UH3 phased award; clear milestones required for transition; clinical trial optional.